Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Inclusion Criteria

• •All subjects
• •Subjects are in good general health.
• •Subjects have provided written informed consent form.
• •All subjects of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug. HCV Subjects
• •Documented clinical history compatible with chronic hepatitis C without cirrhosis.
• •Treatment-naïve
• •HCV Genotype 1